Mounjaro®
Starting from £179.99/mo
Start journey Learn moreGetting started with weight loss injections is a clinical process, not a transaction. Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are prescription-only medicines in the UK, which means a qualified prescriber must assess your suitability before a single pen is dispensed. Support is not an optional add-on — it is built into the legal and clinical framework around these medicines. Here is how that plays out in practice, and what good ongoing support should include at each stage.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
There is a persistent idea that getting a weight loss injection is mostly about meeting a BMI number. In practice, the assessment covers considerably more than that. A prescriber will look at your current weight, health conditions, medicines you already take, and any circumstances that would make these treatments unsuitable, pregnancy, a history of certain conditions, specific GI problems. BMI is the starting point, not the whole picture.
For licensed weight loss injections in the UK, the private eligibility threshold is a BMI of 30 or above, or 27 or above if you have at least one weight-related condition such as high blood pressure, raised cholesterol, type 2 diabetes or prediabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. None of that replaces a prescriber's clinical judgement, two people with identical BMI readings may get different outcomes from an assessment.
At nume, a GPhC-registered Independent Prescriber personally reads every consultation the same day it arrives. Your GP is also notified in line with GPhC guidance. The NHS England guidance on weight management injections sets out what wraparound care should involve; our process is designed around those same principles.
If you want to understand more about which injection is licensed for what, the overview of what injection helps with weight loss in the UK covers the licensed options clearly.
The first pen is a tolerability dose. With Mounjaro that means 2.5 mg; with Wegovy the path begins at 0.25 mg. The job of that opening period is to let your digestive system adjust before any meaningful therapeutic effect builds. Side effects (nausea, loose stools, reduced appetite, occasional fatigue or headaches) are most common in the first few weeks and after each step up in dose. They usually settle. They can also catch people off guard if nobody prepared them.
Good support at this stage means you can ask questions when something feels off. Not a FAQ page. An actual clinical team you can reach. At nume, aftercare is available seven days a week. That matters most in week two of a new dose, not at the six-month review.
There are practical habits that genuinely help: eating slowly, stopping when full rather than finishing the plate, keeping protein intake up, staying well hydrated. These are not substitutes for the medicine, they work alongside it. Your prescriber or the Patient Information Leaflet that comes with your pen will cover these; the NHS tirzepatide page also explains what to expect from common side effects.
If you experience severe, persistent stomach pain that spreads to your back, with or without vomiting, seek urgent medical attention, this can be a sign of pancreatitis, a known but infrequent side effect that the MHRA has specifically flagged. Any suspected side effects can be reported via the Yellow Card scheme at yellowcard.mhra.gov.uk.
Here is where many online services fall short. Issuing a starter prescription is the easier part. What takes actual clinical infrastructure is reviewing every single repeat, checking progress, re-assessing suitability, looking at whether a dose increase is appropriate, and catching anything that has changed in the months since the first prescription.
At nume, no repeat is issued without a clinical re-review. Dose increases require supporting evidence. That is not bureaucracy for its own sake, it reflects how these medicines are designed to work. Tirzepatide, for example, moves through six dose steps from 2.5 mg to 15 mg; the published trial evidence behind the headline weight-loss figures was built on a structured titration over many months, not a jump straight to the highest dose.
Cost is worth being honest about at this stage. A three-month supply can look like an attractive way to reduce per-pen cost, and there is a practical case for it, but only once you have established that a given dose agrees with you and a prescriber has confirmed you are ready to continue. The three-month supply option is worth reading about once you are past the titration phase. If you are still comparing what different providers include in their quoted price, the guide to cheap weight loss injections covers what is often missing from low headline figures.
The NICE appraisal of tirzepatide (TA1026) includes a review point at six months: if less than 5% of body weight has been lost at the highest tolerated dose, continuing treatment is reassessed. That built-in checkpoint is a feature of responsible prescribing, not a complication.
Clinical support across the duration of treatment is associated with better adherence and better outcomes. That is not a surprising finding, it is what you would expect when people know someone is paying attention. What it means practically: a place to flag concerns without waiting for the next scheduled appointment, someone who notices if a dose step was skipped, and clinical eyes on each repeat rather than an automated renewal.
It also means you are less likely to stop treatment at the first difficult week. Early nausea in week three of 5 mg is not a reason to abandon a prescription that was clinically appropriate. Knowing that is fine, and having a team confirm it, keeps people on track.
If you want a broader picture of the treatment landscape before deciding anything, our treatment overview sets out both injectable and oral options, and if you are exploring a specific option you can read more about injections that help with weight loss to understand how the available treatments compare. Our clinical team brings the prescribing experience that makes the support side of this service substantive rather than nominal. When you are ready to check whether you meet the eligibility criteria, start your free consultation and a prescriber will review your answers the same day.
We also have dedicated guidance for people with specific health conditions; if you have been diagnosed with polycystic ovary syndrome, for example, our page on whether weight loss injections can help with PCOS explains what the evidence currently shows.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.